[EN] IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS [FR] COMPOSÉS D'IMIDAZOPYRIDINE ET D'IMIDAZOPYRAZINE UTILISÉS COMME INHIBITEURS DE KINASE
[EN] IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS [FR] COMPOSÉS D'IMIDAZOPYRIDINE ET D'IMIDAZOPYRAZINE UTILISÉS COMME INHIBITEURS DE KINASE
IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS
申请人:Hynes John
公开号:US20110288085A1
公开(公告)日:2011-11-24
A compound of Formula (I) or Formula (II) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) or Formula (II), and methods of treating conditions associated with the activity of p38 kinase.
Triazolopyridine Compounds Useful As Kinase Inhibitors
申请人:Hynes John
公开号:US20110077243A1
公开(公告)日:2011-03-31
A compound of Formula (I) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I), and methods of treating conditions associated with the activity of p38 kinase.
Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
申请人:Bristol-Myers Squibb Company
公开号:US08338604B2
公开(公告)日:2012-12-25
A compound of Formula (I) or Formula (II) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) or Formula (II), and methods of treating conditions associated with the activity of p38 kinase.
Triazolopyridine compounds useful as kinase inhibitors
申请人:Hynes John
公开号:US08410128B2
公开(公告)日:2013-04-02
A compound of Formula (I) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I), and methods of treating conditions associated with the activity of p38 kinase.
[EN] UREA OREXIN RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR DE L'OREXINE D'URÉE
申请人:MERCK SHARP & DOHME
公开号:WO2022132696A1
公开(公告)日:2022-06-23
The present invention is directed to urea compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.